ACS and AMI - Therapy (Clinical Pharmacology) Flashcards

1
Q

What comprises acute coronary syndromes?

A

•Increase myocardial oxygen supply

–through coronary vasodilation.

Decrease myocardial oxygen demand

–Decrease in heart rate,

–Decrease blood pressure,

–Decrease preload or myocardial contractility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Common pathogenesis of ACS?

A

•Common pathogenesis

–atherosclerotic plaque rupture or erosion

–superimposed platelet aggregation and thrombosis

– Vasospasm, and vasoconstriction

–subtotal or transient total occlusion of vessel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the goal of pharmacotherapy?

A

•Increase myocardial oxygen supply

–through coronary vasodilation.

•Decrease myocardial oxygen demand

–Decrease in heart rate,

–Decrease blood pressure,

–Decrease preload or myocardial contractility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the likelihood of coronary thrombus occlusion of the infarct artery in STEMI?

A

Highe likelihood, •Angiographic evidence of coronary thrombus formation is seen in more than 90% of patients with STEMI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Where does the thrombus which occludes a coronary artery in STEMI lie?

A

Overlies an atheromatous plaque

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

When is thrombolysis indicated?

A

If no PCI within 2 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is thrombolysis by serine proteases achieved?

A

Work by converting plasminogen to the fibrinolytic agent plasmin.

Plasmin lyses clot by breaking down the fibrinogen and fibrin contained in a clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the two categories of fibrinolytics?

A

Fibrin-specific agents

Non–fibrin-specific agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Give examples of fibrin specific agents

A
  • alteplase,
  • reteplase,
  • tenecteplase

All catalyse conversion of plasminogen to plasmin in the absence of fibrin.

(assuming these agents are therefore inhibited by fibrin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Give examples of non fibrin specific agents

A

streptokinase,

which catalyses systemic fibrinolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the contraindications for thrombolysis?

A
  • Prior intracranial hemorrhage (ICH)
  • Known structural cerebral vascular lesion
  • Known malignant intracranial neoplasm
  • Ischaemic stroke within 3 months
  • Suspected aortic dissection
  • Active bleeding or bleeding diathesis (excluding menses)
  • Significant closed-head trauma or facial trauma within 3 months
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the benefits of thrombolysis?

A
  • 23% reduction in mortality
  • 39% when used with aspirin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the acute coronary syndrome medical treatment protocol if there is no evidence of STEMI?

A
  • Aspirin
  • Tigagrelor/Clopidogrel (ADP receptor blockers)
  • Fondaparinux/LMW heparin
  • Intravenous nitrate
  • Analgesia
  • Beta Blockers

Other Medicines:

  • prasugrel
  • GIIbIIIa receptor blockers
  • Statins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the effect of an ADP receptor blocker?

A

Stops binding of ADP to ADP receptors (P2Y12) Therefore no activation of platelets.

(In normal circumstances an activated platelet produces, thromboxane A2, ADP, Fibrinogen and VWF. Thromboxane activates GP2b/3a receptors which now bind to fibrinogen and cause platelet aggregation - platelet plug and clot)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is management to reduce risk from NSTEMI?

A
  • PCI or CABG
  • Aspirin
  • Clopidogrel, prasugrel, ticagrelor, ticlopidine or cilostazol
  • Heparin (LMWH)
  • Fondaparinux
  • GIIb/IIIa receptor blockers
  • Statins
  • B blockers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Platelet aggregation is important in the pathogenesis of what diseases?

A

•angina, unstable angina and acute MI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the effect of aspirin on thromboxane A2 production?

A

•Aspirin is a potent inhibitor of platelet thromboxane A2 production

18
Q

What is the effect of thromboxane?

A

Stimulates platelet aggregation and vasoconstriction

19
Q

What is the effect of daily use of aspirin on acute MI?

A

–reduce mortality by 23%

–in combination with thrombolysis reduce mortality by 42% and reinfarction by 52%

20
Q

What is the effect of daily use of aspirin on unstable angina?

A

–reduce MI and death by 50%

21
Q

What is the effect of daily use of aspirin on secondary prevention?

A

Reduces reinfarction by 32% and combined vascular events by 25%

22
Q

Is there a significant difference in the effectiveness of higher dose aspirin versus lower dose aspirin?

A

No - therefore always a good idea to use low dose aspirin

23
Q

How does clopidogrel work?

A
  • Clopidogrel is a prodrug
  • Inhibits ADP receptor activated platelet aggregation.
  • Specifically and irreversibly inhibits the P2Y12 ADP receptor which is important in aggregation of platelets and cross-linking by fibrin
24
Q

What is the effect of ADP on platelet gpIIb/IIIa receptors?

A

Changes platelet gpIIb/IIIa receptors to induce binding to fibrinogen

25
Q

What is the effect of ADP receptor blockers on the GP IIb/IIIa pathway?

A

•The IIb/IIIa complex is a receptor for fibrinogen, fibronectin and von WF. Activation of this receptor complex is the “final common pathway” for platelet aggregation and cross-linking of platelets by fibrin. However if ADP is blocked there is no activation of the 2b/3a complex and so no platelet aggregation

26
Q

What is clopidogrel used with?

A
  • Always used in combination with aspirin
  • Relative risk reduction of 21% when used together with aspirin.
27
Q

Why do some of the population have clopidogrel resistance?

A

Clopidogrel is a prodrug, activated by Cyp 2c19

•14% of population have low CYP2C19 levels and demonstrate resistance to clopidogrel

28
Q

What is the effect of prasugrel?

A

ADP receptor inhibitor like clopidogrel

Compared to clopidogrel prasugrel inhibits ADP–induced platelet aggregation more rapidly, more consistently,

29
Q

What type of heparin is used as an integral part of the acute coronary syndrome protocol?

A

Low molecular weight heparin

30
Q

What are the different examples of low molecular weight heparin?

A
  • Enoxaparin
  • Dalteparin
  • Tinzeparin
  • Fondaparinux
31
Q

What is heparin?

A

A compound occurring in the liver and other tissues which inhibits blood coagulation. A sulphur-containing polysaccharide, it is used as an anticoagulant in the treatment of thrombosis.

32
Q

What is the benefit of fondaparinux over enoxaparin?

A

Reduces Death/MI/RI/Major Bleeding more significantly

33
Q

Can you name GP2b/3a receptor inhibitor?

A

•abciximab, tirofiban

34
Q

What is the effect of a glycoprotein receptor inhibitor?

A

Prevents the conformational change in platelet GP2b/3a inhibitor which would normally cause binding with fibrinogen - no aid of platelet aggregation

35
Q

What is the major adverse effect of glycoprotein 2b/3a?

A

Bleeding

–major bleeding occurrs in 1.4 % of patients

–minor bleeding in 10.5 %.

–Blood transfusion required to terminate bleeding and to improve bleeding-related anaemia in 4.0 % of all patients.

Thrombocytopenia (Thrombocytopenia is a condition in which you have a low blood platelet count) was more often with tirofiban + heparin (1.5 %) than with heparin (0.8 %)

36
Q

What are beta blockers used for post MI?

A

In the treatment of acute MI

For secondary prevention in the survivors of an acute MI.

37
Q

Give two examples of beta blockers

A

I.V.atenolol or metoprolol

38
Q

When is oral beta blockade startes?

A

Started weeks or months post MI reduce cardiac death by 22% and second MI by 26%

39
Q

What is the effect of beta blockers?

A

•Beta-blockers competitively inhibit the myocardial effects of circulating catecholamines and reduce myocardial oxygen consumption by lowering heart rate, blood pressure and myocardial contractility.

Any of a class of aromatic amines which includes a number of neurotransmitters such as adrenaline and dopamine.

40
Q

When is it a bad idea to give patients beta blockers?

A

Patients at risk of developing cardiogenic shock (i.e. age >70 years, heart rate >110 beats/min, systolic blood pressure < 120 mmHg)

Cardiogenic shock is a condition in which your heart suddenly can’t pump enough blood to meet your body’s needs.

Avoid in these and patients with symptoms possibly related to coronary vasospasm or cocaine use.